This measure has amended some existing listings for the Pharmaceutical Benefits Scheme and added some new items from 1 April 2013. The Pharmaceutical Benefits Scheme gives Australian residents and eligible overseas visitors access to affordable medicines.
Description of the measure
The changes include:
- boceprevir and telaprevir – new listing to allow the medicine to be used for the treatment of chronic Hepatitis C in adults
- levonorgestrel with ethinyloestradiol – new listing of a combined oral contraceptive pill
- rotigotine – new listing of a dosage form (patch) to be used for the treatment of advanced Parkinson's disease
- sitagliptin and simvastatin – new listing to allow a combined medicine to be used for the treatment of type 2 diabetes and high cholesterol
- strontium ranelate – amended listing to allow the medicine to be used for the treatment of osteoporosis in males aged 70 years or older.
Questions and answers
Who will be affected by this measure?
Eligible Australian residents and eligible overseas visitors will be able to access these medicines under the Pharmaceutical Benefits Scheme if prescribed by their health professional. Health professionals including pharmacists, general practitioners, specialists and nurse practitioners will need to be aware of these changes.
Am I eligible for this measure?
The Schedule of Pharmaceutical Benefits has been updated to show the new and amended listings. Health professionals will decide if their patient is eligible. Some of these medicines will require patients to meet particular restriction criteria listed in the Schedule of Pharmaceutical Benefits.
When will this measure start and finish?
The new and amended listings on the Schedule of Pharmaceutical Benefits started on 1 April 2013. This is an ongoing measure.